Diethylstilbestrol syndrome

Diethylstilbestrol (DES) syndrome refers to the constellation of congenital anomalies and long-term health consequences observed in individuals who were exposed in utero to diethylstilbestrol, a synthetic nonsteroidal estrogen that was widely prescribed to pregnant women from the 1940s through the early 1970s to prevent miscarriage and pregnancy complications. DES syndrome is classified as a teratogenic condition rather than a genetic disorder, as it results from prenatal environmental exposure. The syndrome primarily affects the reproductive system. In females exposed in utero (often called 'DES daughters'), characteristic findings include structural abnormalities of the uterus (T-shaped uterus, hypoplastic uterus), cervical abnormalities (cervical collar, cockscomb cervix, cervical hypoplasia), and vaginal adenosis. DES daughters have a significantly increased risk of clear cell adenocarcinoma of the vagina and cervix, as well as increased rates of infertility, ectopic pregnancy, preterm delivery, and miscarriage. Males exposed in utero ('DES sons') may present with epididymal cysts, cryptorchidism, testicular hypoplasia, and microphallus, and may have an increased risk of genitourinary abnormalities. There is no specific curative treatment for DES syndrome. Management focuses on surveillance and early detection of associated complications, particularly cancer screening in DES daughters through regular gynecological examinations including careful inspection and palpation of the vagina and cervix. Fertility issues may be addressed with assisted reproductive technologies. Psychological support is also recommended given the emotional burden of the diagnosis. Research continues into potential transgenerational effects in the grandchildren of women who took DES during pregnancy.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Diethylstilbestrol syndrome